Roche Forecast, price target & analysts
Roche Target price 2025 - Analyst rating & recommendation
Roche Classifications & Recommendation:
Roche Price Target
| Target Price | CHF310.90 |
| Price | CHF255.60 |
| Potential | 21.64% |
| Number of Estimates | 20 |
| 20 Analysts have issued a price target Roche 2026 . The average Roche target price is CHF310.90. This is 21.64% higher than the current stock price. The highest price target is CHF448.00 75.27% , the lowest is CHF230.00 10.02% . | |
| A rating was issued by 25 analysts: 12 Analysts recommend Roche to buy, 9 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Roche stock has an average upside potential 2026 of 21.64% . Most analysts recommend the Roche stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Billion CHF | 60.50 | 64.35 |
| 3.03% | 6.38% | |
| EBITDA Margin | 35.81% | 39.71% |
| 6.07% | 10.89% | |
| Net Margin | 13.66% | 23.24% |
| 29.92% | 70.12% |
20 Analysts have issued a sales forecast Roche 2025 . The average Roche sales estimate is CHF64.4b . This is 6.38% higher than the revenue of the last 12 months(TTM). The highest sales forecast is CHF67.0b 10.74% , the lowest is CHF62.7b 3.60% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | CHF60.5b | 3.03% |
|---|---|---|
| 2025 | CHF64.4b | 6.38% |
| 2026 | CHF67.3b | 4.55% |
| 2027 | CHF69.8b | 3.74% |
| 2028 | CHF72.5b | 3.94% |
| 2029 | CHF75.1b | 3.53% |
18 Analysts have issued an Roche EBITDA forecast 2025. The average Roche EBITDA estimate is CHF25.6b . This is 21.48% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is CHF27.1b 29.03% , the lowest is CHF21.9b 4.08% .
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Estimates
| 2024 | CHF21.7b | 9.28% |
|---|---|---|
| 2025 | CHF25.6b | 17.97% |
| 2026 | CHF26.9b | 5.16% |
| 2027 | CHF27.8b | 3.30% |
| 2028 | CHF29.6b | 6.77% |
| 2029 | CHF29.4b | 0.67% |
EBITDA Margin
| 2024 | 35.81% | 6.07% |
|---|---|---|
| 2025 | 39.71% | 10.89% |
| 2026 | 39.94% | 0.58% |
| 2027 | 39.77% | 0.43% |
| 2028 | 40.86% | 2.74% |
| 2029 | 39.20% | 4.06% |
14 Roche Analysts have issued a net profit forecast 2025. The average Roche net profit estimate is CHF15.0b . This is 80.94% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is CHF17.0b 105.34% , the lowest is CHF10.4b 25.99% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | CHF8.3b | 27.80% |
|---|---|---|
| 2025 | CHF15.0b | 80.94% |
| 2026 | CHF16.1b | 7.51% |
| 2027 | CHF16.9b | 5.17% |
| 2028 | CHF17.0b | 0.79% |
| 2029 | CHF18.9b | 10.79% |
Net Margin
| 2024 | 13.66% | 29.92% |
|---|---|---|
| 2025 | 23.24% | 70.12% |
| 2026 | 23.89% | 2.80% |
| 2027 | 24.22% | 1.38% |
| 2028 | 23.49% | 3.01% |
| 2029 | 25.14% | 7.02% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share CHF | 10.39 | 18.80 |
| 27.80% | 80.94% | |
| P/E | 13.60 | |
| EV/Sales | 3.52 |
14 Analysts have issued a Roche forecast for earnings per share. The average Roche EPS is CHF18.80 . This is 80.94% higher than earnings per share in the financial year 2024. The highest EPS forecast is CHF21.33 105.29% , the lowest is CHF13.09 25.99% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | CHF10.39 | 27.80% |
|---|---|---|
| 2025 | CHF18.80 | 80.94% |
| 2026 | CHF20.21 | 7.50% |
| 2027 | CHF21.26 | 5.20% |
| 2028 | CHF21.42 | 0.75% |
| 2029 | CHF23.74 | 10.83% |
P/E ratio
| Current | 24.60 | 57.49% |
|---|---|---|
| 2025 | 13.60 | 44.72% |
| 2026 | 12.65 | 6.99% |
| 2027 | 12.03 | 4.90% |
| 2028 | 11.93 | 0.83% |
| 2029 | 10.77 | 9.72% |
Based on analysts' sales estimates for 2025, the Roche stock is valued at an EV/Sales of 3.52 and an P/S ratio of 3.16 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 3.75 | 8.07% |
|---|---|---|
| 2025 | 3.52 | 6.05% |
| 2026 | 3.37 | 4.35% |
| 2027 | 3.25 | 3.61% |
| 2028 | 3.13 | 3.79% |
| 2029 | 3.02 | 3.41% |
P/S ratio
| Current | 3.36 | 10.01% |
|---|---|---|
| 2025 | 3.16 | 6.00% |
| 2026 | 3.02 | 4.35% |
| 2027 | 2.91 | 3.61% |
| 2028 | 2.80 | 3.79% |
| 2029 | 2.71 | 3.41% |
Current Roche Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| BERENBERG |
Hold
➜
Hold
|
Unchanged | Apr 07 2025 |
| TD COWEN |
Hold
➜
Hold
|
Unchanged | Apr 06 2025 |
| HSBC |
Buy
➜
Buy
|
Unchanged | Mar 23 2025 |
| REDBURN ATLANTIC |
Buy
➜
Buy
|
Unchanged | Mar 21 2025 |
| JEFFERIES |
Hold
➜
Hold
|
Unchanged | Mar 11 2025 |
| STIFEL EUROPE |
Hold
➜
Hold
|
Unchanged | Mar 02 2025 |
| DZ BANK |
Buy
➜
Buy
|
Unchanged | Feb 02 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
BERENBERG:
Hold
➜
Hold
|
Apr 07 2025 |
|
Unchanged
TD COWEN:
Hold
➜
Hold
|
Apr 06 2025 |
|
Unchanged
HSBC:
Buy
➜
Buy
|
Mar 23 2025 |
|
Unchanged
REDBURN ATLANTIC:
Buy
➜
Buy
|
Mar 21 2025 |
|
Unchanged
JEFFERIES:
Hold
➜
Hold
|
Mar 11 2025 |
|
Unchanged
STIFEL EUROPE:
Hold
➜
Hold
|
Mar 02 2025 |
|
Unchanged
DZ BANK:
Buy
➜
Buy
|
Feb 02 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
